The uterine fibroids market was valued at USD 14.39 Billion in 2025, driven by advancements in treatment options across the 8 major markets. The market is expected to grow at a CAGR of 7.30% during the forecast period of 2026-2035, with the values likely to reach USD 29.11 Billion by 2035.
Base Year
Historical Period
Forecast Period
The strong regulatory backing from health authorities is expected to elevate the market value in the coming years.
In May 2024, Aster RV Hospital in Bengaluru made history in South India by successfully removing a 4 kg fibroid from a patient's uterus through laparoscopic surgery. Thus, the utilization of innovative treatments in hospitals is a significant market trend.
Continuous research and development to enhance treatment options is anticipated to boost market value.
Compound Annual Growth Rate
7.3%
Value in USD Billion
2026-2035
*this image is indicative*
Uterine fibroids, which are non-cancerous growths located in the uterus, are frequently seen in women of African descent. Possible symptoms are menstrual bleeding, pelvic pain, frequent urination, bloating, and reproductive problems. Diagnosis is conducted through pelvic exams, imaging procedures, and blood tests, and treatment is tailored according to the symptoms. Increased demand for fertility-preserving treatments and the development of symptomatic treatments are expected to drive the market growth in the forecast period.
Technological Advancement and Innovation in Treatment Options to Drive Market Growth
Advancements in technology and innovation in treatment options are causing a rise in demand in the market for uterine fibroids. UConn Health, a hospital in the United States, has implemented the Sonata® treatment, demonstrating a revolutionary option to standard surgeries and providing patients with a less invasive choice that allows for quicker recovery and better results. Thus, the advancement in medical technology is one of the primary drivers of the market.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Type
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on the Type to Witness Growth
The uterine fibroid market segmentation, based on type, includes subserosal fibroids, intramural fibroids, submucosal fibroids, and pedunculated fibroids, among others. Submucosal fibroids are expected to dominate the market, with emerging economies experiencing category expansion due to their development in the muscle layer of the uterus. Intramural fibroids are also increasing, impacting fertility rates, and requiring treatment.
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India. The United States is expected to dominate the market share owing to the rising prevalence of uterine fibroids, increasing pregnancy complications due to fibroids, and the approval of novel treatment options.
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc. is a United States-based pharmaceutical company specializing in biopharmaceuticals for cardiovascular, metabolic, and women's health. In January 2024, Pfizer Canada collaborated with Sumitomo Pharma Canada to offer MYFEMBREE® for endometriosis and uterine fibroids in Canada.
AbbVie Inc. based in North Chicago, Illinois, is a pharmaceutical company specializing in the development and commercialization of drugs for chronic and complex diseases. Their focus includes treatments for metabolic, rheumatological, neurological, and skin diseases, as well as hormonal and women's health conditions like hypothyroidism and uterine fibroids.
ObsEva SA is a clinical-stage biopharmaceutical company focusing on developing novel therapies for women's reproductive health and pregnancy. In February 2022, they entered a licensing agreement with Theramex to commercialize Linzagolix, an oral GnRH antagonist for treating uterine fibroids and potentially endometriosis-associated pain.
Bayer AG is a German pharmaceutical and biotechnology company that focuses on innovative solutions for disease prevention and treatment. They are a key player in the uterine fibroid market, with research efforts on drugs like Vilaprisan for treating symptomatic uterine fibroids.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other players in the market include AstraZeneca.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share